For: | Shakado S, Sakisaka S, Chayama K, Okanoue T, Toyoda J, Izumi N, Matsumoto A, Takehara T, Ido A, Hiasa Y, Yoshioka K, Nomura H, Ueno Y, Seike M, Kumada H. Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development. World J Hepatol 2015; 7(27): 2757-2764 [PMID: 26644819 DOI: 10.4254/wjh.v7.i27.2757] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v7/i27/2757.htm |
Number | Citing Articles |
1 |
Yue Chang, Baiqing Liu, Haiyan Niu, Zhenguo Wang, Shihai Xia, Hai Li. Value of anti-p53 antibody as a biomarker for hepatocellular carcinoma. Medicine 2020; 99(34): e21887 doi: 10.1097/MD.0000000000021887
|
2 |
Bing-yao Pang, Yan Leng, Xiaoli Wang, Yi-qiang Wang, Li-hong Jiang. A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma. Annals of Medicine 2023; 55(1): 42 doi: 10.1080/07853890.2022.2153163
|
3 |
Takashi Tanaka, Kazuhide Takata, Takashi Miyayama, Kumiko Shibata, Hiromi Fukuda, Ryo Yamauchi, Atsushi Fukunaga, Keiji Yokoyama, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai. Long-term outcome and eligibility of radiofrequency ablation for hepatocellular carcinoma over 3.0 cm in diameter. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-43516-w
|
4 |
Massimiliano Berretta, Carla Cavaliere, Lara Alessandrini, Brigida Stanzione, Gaetano Facchini, Luca Balestreri, Tiziana Perin, Vincenzo Canzonieri. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget 2017; 8(8): 14192 doi: 10.18632/oncotarget.13929
|